Cited 0 times in
Psychometric analysis of the Korean version of the high-dose chemotherapy specific quality of life questionnaire module from the European Organization for Research and Treatment of Cancer (EORTC QLQ-HDC29)
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김진석 | - |
dc.date.accessioned | 2017-10-26T07:58:48Z | - |
dc.date.available | 2017-10-26T07:58:48Z | - |
dc.date.issued | 2016 | - |
dc.identifier.issn | 0962-9343 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/152773 | - |
dc.description.abstract | PURPOSE: We evaluated the psychometric properties of the Korean version of the European Organization for Research and Treatment of Cancer high-dose chemotherapy specific quality of life questionnaire module (EORTC QLQ-HDC29) when implemented with Korean patients by conducting a multicenter, longitudinal study in three Korean hospitals. METHODS: A total of 226 patients who scheduled to receive the HDC followed by hematopoietic stem cell transplantation (HSCT) were enrolled. The patients were asked to complete three questionnaires [the EORTC Core Questionnaire (QLQ-C30), QLQ-HDC29, and the Functional Assessment of Cancer Therapy-Bone Marrow Transplantation] at four points in time: before HSCT and 100, 180, and 365 days after HSCT. Standard validity and reliability analyses were performed. RESULTS: Internal consistency of the QLQ-HDC29 was generally acceptable, as tested by Cronbach's α, except for the scales body image and the inpatient issues. Cronbach's α values for the Korean version of the QLQ-HDC29 were almost in accordance with results of the original version, except for the scales body image (lower to the original QLQ-HDC29, α = 0.73) and impact on family (higher to the original QLQ-HDC29, α = 0.52). Known-group comparison analyses showed significantly higher symptom burdens in patients with poor performance status or graft versus host disease (similar to the original QLQ-HDC29). The QLQ-HDC29 indicated good convergent and discriminant validity and showed responsiveness to changes in line with a clinical course over time after HSCT. CONCLUSIONS: The QLQ-HDC29 is generally reliable and adequate to assess QoL in Korean patients undergoing HDC followed by HSCT. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | Springer Netherlands | - |
dc.relation.isPartOf | QUALITY OF LIFE RESEARCH | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Aged, 80 and over | - |
dc.subject.MESH | Antineoplastic Agents/administration & dosage* | - |
dc.subject.MESH | Dose-Response Relationship, Drug* | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Hematopoietic Stem Cell Transplantation | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Longitudinal Studies | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Neoplasms/drug therapy | - |
dc.subject.MESH | Psychometrics | - |
dc.subject.MESH | Quality of Life/psychology* | - |
dc.subject.MESH | Reproducibility of Results | - |
dc.subject.MESH | Republic of Korea | - |
dc.subject.MESH | Sickness Impact Profile | - |
dc.subject.MESH | Surveys and Questionnaires* | - |
dc.subject.MESH | Tertiary Care Centers | - |
dc.title | Psychometric analysis of the Korean version of the high-dose chemotherapy specific quality of life questionnaire module from the European Organization for Research and Treatment of Cancer (EORTC QLQ-HDC29) | - |
dc.type | Article | - |
dc.publisher.location | Netherlands | - |
dc.contributor.college | College of Medicine | - |
dc.contributor.department | Dept. of Internal Medicine | - |
dc.contributor.googleauthor | Kyung Im Kim | - |
dc.contributor.googleauthor | Jae Hyun Kim | - |
dc.contributor.googleauthor | Eun Hee Ji | - |
dc.contributor.googleauthor | Jun Ho Jang | - |
dc.contributor.googleauthor | Jin Seok Kim | - |
dc.contributor.googleauthor | Ji-Hyun Kwon | - |
dc.contributor.googleauthor | Inho Kim | - |
dc.contributor.googleauthor | Seonyang Park | - |
dc.contributor.googleauthor | Galina Velikova | - |
dc.contributor.googleauthor | Sung-Soo Yoon | - |
dc.contributor.googleauthor | Jung Mi Oh | - |
dc.identifier.doi | 10.1007/s11136-015-1121-5 | - |
dc.contributor.localId | A01017 | - |
dc.relation.journalcode | J02586 | - |
dc.identifier.eissn | 1573-2649 | - |
dc.identifier.pmid | 26342931 | - |
dc.identifier.url | https://link.springer.com/article/10.1007%2Fs11136-015-1121-5 | - |
dc.subject.keyword | Hematopoietic stem cell transplantation | - |
dc.subject.keyword | High-dose chemotherapy | - |
dc.subject.keyword | QLQ-HDC29 | - |
dc.subject.keyword | Quality of life | - |
dc.subject.keyword | Validation | - |
dc.contributor.alternativeName | Kim, Jin Seok | - |
dc.contributor.affiliatedAuthor | Kim, Jin Seok | - |
dc.citation.volume | 25 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 881 | - |
dc.citation.endPage | 890 | - |
dc.identifier.bibliographicCitation | QUALITY OF LIFE RESEARCH, Vol.25(4) : 881-890, 2016 | - |
dc.date.modified | 2017-10-24 | - |
dc.identifier.rimsid | 39781 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.